REG - Yourgene Health PLC - Exercise of Warrants and Options

Yourgene HealthAnnouncement

20/05/2020 07:01

RNS Number : 4070N
  
Yourgene Health PLC
  
20 May 2020
  
 

 
Yourgene Health plc
("Yourgene" or the "Company")
 
Exercise of Warrants and Options
 
Manchester, UK - 20 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, received notification of the following exercise of options and warrants:-
 
·    For the exercise of options over 6,437,565 ordinary shares in the Company at an exercise price of 10 pence per share providing the Company with proceeds of £643,756.50 ("Options Exercise"). The options are being exercised by two former employees prior to the expiry of the option.
 
·    For the exercise of warrants over 1,411,427 ordinary shares in the Company at an exercise price of 11 pence per share providing the Company with proceeds of £155,256.97 ("Warrant Exercise"). The warrant is being exercised by an adviser on the 2014 Admission to AIM prior to the expiry of the warrants.
 
Application will be made to the London Stock Exchange to admit the aggregate 7,848,992 new ordinary shares resulting from the Options Exercise and Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 26 May 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.
 
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 624,331,197 ordinary shares of 0.1p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 




Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com 




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Director of Marketing


 




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


 




 


 




Stifel Nicolaus Europe Limited (Sole Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




 


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 




Paul McManus / Lianne Cawthorne 


Mob: 07980 541 893 / Mob: 07584 391 303  



 
 
 



 
 
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
 
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
IOEUKVKRRWUVAAR